Teladoc Health Stock Slides On Q1 Earnings As Company Cuts FY25 Guidance

Teladoc Health Inc TDOC reported financial results for the first quarter Wednesday after the bell. Here’s a rundown of the report.

Q1 Earnings: Teladoc reported first-quarter revenue of $629.4 million, beating the consensus estimate of $619.29 million, according to Benzinga Pro. The company reported a first-quarter loss of 53 cents per share, missing analyst estimates for a loss of 34 cents per share.

Total revenue was down 3% on a year-over-year basis. Revenue fell 4% year-over-year in the U.S., but International revenue grew 6% year-over-year. Here’s a breakdown of revenue by segment:

• Integrated Care revenue: up 3% to $389.5 million

• BetterHelp revenue: down 11% to $239.9 million

• Access Fees revenue: down 6% to $525.7 million

• Other revenue: up 16% to $103.6 million

Cash flow from operations totaled $15.9 million in the quarter. The company said capital expenditures and capitalized software development costs came in at $31.6 million. Teladoc ended the period with approximately $1.19 billion in cash and cash equivalents.

“We are pleased with the solid start to 2025. Consolidated revenue and adjusted EBITDA were towards the higher end of our first quarter guidance ranges, including our Integrated Care segment being above our ranges for both measures and BetterHelp segment results in the upper half of our ranges as well,” said Chuck Divita, CEO of Teladoc Health.

“We also continue to make progress towards strategic priorities aimed at driving sustainable performance, including advancing our position in virtual mental health.”

In connection with the earnings release, Teladoc also announced that it acquired virtual mental health therapy provider UpLift for $30 million in an all-cash transaction. The deal also includes up to $15 million in additional contingent earnout consideration.

Guidance: Teladoc expects second-quarter revenue of $614 million to $633 million, and full-year revenue of $2.47 billion to $2.58 billion. Analysts are anticipating full-year revenue of $2.52 billion, according to Benzinga Pro.

The company also lowered its full-year earnings outlook. Teladoc anticipates a 2025 loss of 90 cents to $1.40 per share, down from prior guidance for a loss of 50 cents to $1.10 per share. Analysts are forecasting a loss of 93 cents per share.

Teladoc executives are currently discussing the quarter on a call with investors and analysts that got started at 4:30 p.m. ET

TDOC Price Action: Teladoc shares were down 5.42% in after-hours, trading at $6.80 at the time of publication on Wednesday, according to Benzinga Pro.

Read Next:

• ‘Sell In May And Go Away’ Looks Outdated As May–July Data Signal Bullish S&P 500 Seasonality

Photo: courtesy of Teladoc Health.